



Intuitive Surgical Receives FDA Clearance for Latest da Vinci® Robotic-Assisted Surgical System

May 30, 2017

New da Vinci X™ Surgical System provides lower-cost, robotic-assisted surgical option for hospitals, surgeons

SUNNYVALE, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- Intuitive Surgical, a global technology leader in robotic-assisted, minimally invasive surgery, announced today that its new *da Vinci X* Surgical System received FDA clearance in the United States. The *da Vinci X* System will provide surgeons and hospitals with access to some of the most advanced robotic-assisted surgery technology at a lower cost. FDA clearance of the *da Vinci X* System follows CE Mark, which was announced in April.

A photo accompanying this announcement is available at <http://www.globenewswire.com/NewsRoom/AttachmentNg/a5827d84-70f1-49ee-9aed-7fae5c0ecca2>

The launch of the *da Vinci X* System underscores Intuitive's commitment to meeting customers' needs with a strong value-oriented portfolio and an array of financing options.

"This new system enables access to Intuitive's leading and proven robotic-assisted surgical technology at a lower price point," said Dr. Gary Guthart, CEO of Intuitive Surgical. "Customers around the globe have different needs from a clinical, cost and technology perspective; Intuitive's goal is to meet those needs by providing a range of products and solutions: the *da Vinci X* System helps us continue to do so."

The *da Vinci X* System offers surgeons and hospitals access to Intuitive's portfolio of advanced, innovative robotic-assisted surgical technologies – and its full ecosystem of programs, support, services, and solutions – at a lower price. The System uses the same vision cart and surgeon console that are found on our flagship product, the *da Vinci Xi*® System, enabling our customers the option of adding advanced capabilities, and providing a pathway for upgrading should they choose to do so as their practice and needs grow.

The *da Vinci X* System enables optimized, focused-quadrant surgery including procedures like prostatectomy, partial nephrectomy, benign hysterectomy and sacrocolpopexy, among others. The System features flexible port placement and 3D digital optics, while incorporating the same advanced instruments and accessories as Intuitive's flagship system. The new system drives operational efficiencies through set-up technology that uses voice and laser guidance, drape design that simplifies surgery prep, and a lightweight, fully integrated endoscope.

"The *da Vinci X* System is a value-oriented option for hospitals that are just starting their robotic-assisted surgical program and for our existing customers who want to expand their existing robotics programs," said Henry Charlton, Senior Vice President of U.S. Sales. "As customers' needs grow, the *da Vinci X* System can grow with them. The *da Vinci X* System enables our customers to take immediate advantage of Intuitive's full ecosystem of support and services."

The *da Vinci X* System will be available for sale in the U.S. later this year.

About Intuitive Surgical, Inc.

Intuitive Surgical, Inc. (Nasdaq:ISRG), headquartered in Sunnyvale, Calif., is a global technology leader in robotic-assisted, minimally invasive surgery. Intuitive Surgical develops, manufactures and markets the *da Vinci* Surgical System.

About the *da Vinci* Surgical System

There are several models of the *da Vinci* Surgical System. The *da Vinci* Surgical Systems are designed to help surgeons perform minimally invasive surgery. *da Vinci* Systems are not programmed to perform surgery on their own. Instead, the procedure is performed entirely by a surgeon who controls the system. *da Vinci* Systems offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels and forceps) that are designed to help with precise dissection and reconstruction deep inside the body.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding regulatory clearances to market the *da Vinci X* System around the world. These forward-looking statements are necessarily estimates reflecting the best judgment of our management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements should, therefore, be considered in light of various important factors, including those under the heading "Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2016, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. Statements using words such as "estimates," "projects," "believes," "anticipates," "plans," "expects," "intends," "may," "will," "could," "should," "would," "targeted"



The *da Vinci X* Surgical System from Intuitive Surgical

and similar words and expressions are intended to identify forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. We undertake no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.

PN1037898-US Rev A 5/2017

Global Public Affairs
Intuitive Surgical
Email: corp.comm@intusurg.com
U.S. Tel: +1 408.523.7337



Intuitive Surgical, Inc.